Aldeyra Therapeutics, Inc.
ALDXNasdaq
$1.69
↓ -1.7%Jul 17 close · end-of-day
Price
1Y↓ -67.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$101.9M
Enterprise Value
$117.2M
P/E
—
P/S
—
P/B
2.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$27.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-64.9%
ROIC
-39.0%
Debt / Equity
0.4
Net Cash
-$15.3M
Return 1Y
-66.4%
Company profile
Aldeyra Therapeutics, Inc. develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for dry eye diseases and allergic conjunctivitis.
- CEO
- Todd C. Brady
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- Massachusetts
- Website
- aldeyra.com
Management & directors
- Brady Todd CPresident and CEO
- Alfieri MichaelPrincipal Financial Officer
- Machatha StephenChief Development Officer
Roles derived from SEC Form 4 filings.
Earnings
ALDX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.06↓ -64.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$36.4M | -$56.2M | -$62.7M | -$42.8M | -$60.1M | -$35.3M |
| Net income | -$37.6M | -$57.8M | -$62.0M | -$37.5M | -$55.9M | -$33.8M |
| Diluted EPS | — | -$1.07 | -$1.06 | -$0.64 | -$0.94 | -$0.56 |
| Operating cash flow | -$37.5M | -$42.6M | -$56.6M | -$30.3M | -$43.2M | -$33.3M |
| Free cash flow | — | -$42.6M | -$56.7M | -$30.3M | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$18.0M | -$16.1M | -$16.6M | -$10.4M | -$10.2M | -$8.0M | -$6.7M | -$3.5M |
| Net income | -$16.8M | -$15.1M | -$15.8M | -$9.9M | -$9.8M | -$7.7M | -$6.5M | -$3.5M |
| Diluted EPS | -$0.28 | -$0.25 | -$0.27 | -$0.17 | -$0.16 | -$0.13 | -$0.10 | -$0.06 |
| Operating cash flow | -$13.2M | -$8.0M | -$12.0M | -$12.5M | -$8.6M | -$7.0M | -$5.3M | -$5.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 10, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-03 | Brady Todd C· President and CEO | Buy | 250,000 | $1.67 | $418,450.00 | filing |
| 2026-03-19 | DOUGLAS RICHARD | Buy | 70,000 | $1.40 | $98,000.00 | filing |
| 2026-03-18 | Alfieri Michael· Principal Financial Officer | Buy | 5,000 | $1.42 | $7,100.00 | filing |
| 2025-08-13 | Alfieri Michael· Principal Financial Officer | Buy | 2,500 | $5.30 | $13,250.00 | filing |
| 2025-08-11 | Machatha Stephen· Chief Development Officer | Sale | 22,073 | $5.15 | $113,713.47 | filing |
Latest 5 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.